Showing results (181-190 of 276) with videos related to

Sort By:
Pageof 28
British Journal of Haematology|May 23, 2013
High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS studyEmmanuel Gyan, Diane Damotte, Stéphane Courby, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|April 1, 2019
Influence of Donor Type (Sibling versus Matched Unrelated Donor versus Haploidentical Donor) on Outcomes after Clofarabine-Based Reduced-Intensity Conditioning Allograft for Myeloid MalignanciesLouise Bouard, Thierry Guillaume, Pierre Peterlin, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 25, 2025
A First-in-Human Phase I Study of LOXO-338, an Oral Selective Bcl-2 Inhibitor, in Patients With Advanced Hematologic MalignanciesMichal Kwiatek, Guru Subramanian Guru Murthy, Marc Hoffmann, et al.
Bone Marrow Transplantation|February 12, 2022
Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective studyDomitille Costes-Tertrais, Thomas Hueso, Thomas Gastinne, et al.
Haematologica|April 14, 2011
Impact of the use of autologous stem cell transplantation at first relapse both in naive and previously rituximab exposed follicular lymphoma patients treated in the GELA/GOELAMS FL2000 studySteven Le Gouill, Sophie De Guibert, Lucie Planche, et al.
British Journal of Haematology|August 27, 2010
Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95Audrey Simon, Michel Peoch, Philippe Casassus, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 14, 2013
Characteristics of B-cell lymphomas in HIV/HCV-coinfected patients during the combined antiretroviral therapy era: an ANRS CO16 LYMPHOVIR cohort studyBenjamin Terrier, Dominique Costagliola, Sophie Prevot, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|November 28, 2018
Deauville Scores 4 or 5 Assessed by Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Early Post-Allotransplant Is Highly Predictive of Relapse in Lymphoma PatientsLouise Bouard, Caroline Bodet-Milin, Clément Bailly, et al.
Ejhaem|July 6, 2021
Safety and immunogenicity of a first dose of SARS-CoV-2 mRNA vaccine in allogeneic hematopoietic stem-cells recipientsPatrice Chevallier, Marianne Coste-Burel, Amandine Le Bourgeois, et al.
European Journal of Haematology|April 4, 2017
Is allogeneic stem cell transplantation for myelofibrosis still indicated at the time of molecular markers and JAK inhibitors era?Elsa Lestang, Pierre Peterlin, Yannick Le Bris, et al.
Pageof 28